Pre-made Enokizumab benchmark antibody ( Whole mAb, anti-IL9 therapeutic antibody, Anti-HP40/IL-9/P40 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-185

Pre-Made Enokizumab biosimilar, Whole mAb, Anti-IL9 Antibody: Anti-HP40/IL-9/P40 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Enokizumab, also known as MEDI-528, is a humanized IgG1κ type monoclonal antibody direct against the cytokine interleukin-9 (IL-9). This drug was developed by MedImmune and has been investigated in the treatment for asthma.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-185-1mg 1mg 3090 30% 2163

Size: 1mg | 10mg | 100mg



Description

Products Name (INN Index) Pre-Made Enokizumab biosimilar, Whole mAb, Anti-IL9 Antibody: Anti-HP40/IL-9/P40 therapeutic antibody
INN Name Enokizumab
TargetIL9
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2010
Year Recommended2011
CompaniesGenaera Corporation;Ludwig Institute for Cancer Research;MedImmune
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedAsthma
Development Techna